Researchers have published results of experiments in rodents suggesting that lithium, a widely prescribed mood stabilizer, may have value as an adjunct to ketamine therapy in people who suffer from ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for ...
Augmentation was more effective with quetiapine than lithium for treatment-resistant depression in a pragmatic trial. Quetiapine also improved quality-adjusted life years more than lithium. The ...
Please provide your email address to receive an email when new articles are posted on . AL001 by Alzamend Neuro will undergo a phase 2a trial in patients with major depressive disorder. The ...
Lithium is one of the good substitute for antidepressants and is effective for long-term treatment of depression and bipolar disorder, offering mood stabilization and anti-suicidal effects. It reduces ...
ATLANTA--(BUSINESS WIRE)--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for ...
A nationwide Swedish cohort study included 105,495 individuals (mean age, 44.2 years; 62.2% women) diagnosed with bipolar disorder between 2006 and 2021 using data from national registers of inpatient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback